Navigation Links
Novel pathway regulates timing of brain cell development

Brain formation involves the carefully timed production of different types of nerve cells by neural stem cells: neurons are produced first, then astrocytes. Making too much of one kind of cell and too little of another at a given time could lead to brain malformations. In the October 6 issue of Cell, researchers in the Neurobiology Program at Children's Hospital Boston report discovering a new molecular pathway that influences the timing of nerve-cell production.

The pathway--which acts through a novel and unexpected mechanism--inhibits production of astrocytes during the early stages of brain development, thereby favoring the production of neurons. (Astrocytes provide structural and functional support to neurons, but can also regulate their differentiation.) Children's neurobiologist Gabriel Corfas, PhD, senior investigator on the study, says the discovery could have implications for diseases such as Alzheimer's disease, schizophrenia and autism.

One key component of the pathway is a protein called erbB4 that straddles the outer membrane of the neural stem cell. Corfas's team showed that mice lacking erbB4 produced astrocytes earlier in embryonic development than normal. ErbB4 is activated by another protein called neuregulin 1 (NRG1), and then is cut in two by a third critical protein called presenilin, the researchers showed. The half of erbB4 that resides inside the cell--a protein called E4ICD--then joins with other proteins in the cell and travels to the cell nucleus. "Once in the nucleus, E4ICD represses genes that trigger astrocyte production, and thereby inhibits astrocyte formation," explains S. Pablo Sardi, PhD, a postdoctoral fellow at Children's and the study's first author.

Previous studies have found presenilin activity to be altered in Alzheimer's disease, and that erbB4 is abundant around the plaques found in Alzheimer's patients' brains. Taken together, the evidence suggests that presenilin's role in Alzheimer's may have to do, in part, with its effects on erbB4 activity--an effect that was previously unrecognized. ErbB4 signaling also regulates neuronal function and survival, processes that have been implicated in Alzheimer's pathology, the researchers note.

"Our findings raise the intriguing possibility that defects in presenilin-mediated erbB4 signaling could be implicated in the early stages of Alzheimer's disease," Corfas says. "Further studies of erbB4 nuclear signaling could provide important insights into the causes of neurodegeneration."

In addition, the genes for both NRG1 and erbB4 have been linked to schizophrenia. Corfas speculates that premature formation of astrocytes resulting from altered functioning of these genes causes subtle malformations in the brain's circuitry. "Changes in the timing in which different neural cells are produced could lead to alterations in brain wiring," he says. "This would lead to alterations in cognitive function such as those seen in schizophrenia--which is now considered to be a developmental disorder--and potentially in other diseases such as autism."


'"/>

Source:Children's Hospital Boston


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)...  For the thousands of attendees at this year,s International Consumer Electronics ... and biometric measurement devices and services, will be featuring its new line ... A&D Medical,s special CES Exhibit Suite , the new upper arm ... company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... Ca (PRWEB) , ... January 11, 2017 , ... ... U.S. each year and costing healthcare systems more than $23.7 billion, healthcare ... controlling costs. , Among the most common sepsis-causing pathogens are bacteria and ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... company developing an innovative cellular response analysis platform to measure the proteomic function ... Phase I Small Business Innovation Research (SBIR) grant from the National Institute on ...
(Date:1/11/2017)... Rockwall Texas (PRWEB) , ... January 11, 2017 , ... ... Clinics. No Drugs, No Shots and No Surgery for positive back pain relief for ... 150,000 documented positive results worldwide and could be life changing for millions suffering from ...
(Date:1/11/2017)... 11, 2017 AnaptysBio, Inc., a clinical-stage ... on unmet medical needs in inflammation, today announced ... chief financial officer.  Mr. Piscitelli will play a ... as overseeing the company,s accounting and SEC reporting ... welcome Dominic to the senior management team at ...
Breaking Biology Technology: